Oppenheimer Asset Management Inc. grew its holdings in shares of AstraZeneca (NYSE:AZN) by 8.8% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 461,805 shares of the company’s stock after buying an additional 37,416 shares during the period. Oppenheimer Asset Management Inc.’s holdings in AstraZeneca were worth $16,149,000 as of its most recent SEC filing.
Other hedge funds have also made changes to their positions in the company. Pinnacle Wealth Planning Services Inc. bought a new stake in shares of AstraZeneca during the 4th quarter valued at $101,000. Delpha Capital Management LLC bought a new stake in shares of AstraZeneca during the 4th quarter valued at $152,000. Calton & Associates Inc. bought a new stake in shares of AstraZeneca during the 4th quarter valued at $181,000. Whittier Trust Co. boosted its holdings in shares of AstraZeneca by 420.0% during the 1st quarter. Whittier Trust Co. now owns 5,200 shares of the company’s stock valued at $182,000 after buying an additional 4,200 shares in the last quarter. Finally, Green Square Capital LLC bought a new stake in shares of AstraZeneca during the 4th quarter valued at $200,000. Hedge funds and other institutional investors own 15.59% of the company’s stock.
A number of brokerages recently issued reports on AZN. Zacks Investment Research upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Monday, January 22nd. Leerink Swann upped their price target on shares of AstraZeneca from $36.00 to $38.00 and gave the stock a “market perform” rating in a research note on Tuesday, February 6th. Sanford C. Bernstein upped their price target on shares of AstraZeneca from $40.00 to $42.00 and gave the stock an “outperform” rating in a research note on Monday, February 5th. ValuEngine upgraded shares of AstraZeneca from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 3rd. Finally, BMO Capital Markets set a $40.00 price target on shares of AstraZeneca and gave the stock a “buy” rating in a research note on Thursday, March 22nd. Three research analysts have rated the stock with a sell rating, five have given a hold rating and thirteen have assigned a buy rating to the company. AstraZeneca presently has a consensus rating of “Hold” and a consensus price target of $38.12.
AstraZeneca opened at $36.33 on Monday, according to MarketBeat Ratings. The company has a current ratio of 0.80, a quick ratio of 0.62 and a debt-to-equity ratio of 0.93. The stock has a market cap of $92.02 billion, a price-to-earnings ratio of 8.49, a P/E/G ratio of 1.94 and a beta of 0.61. AstraZeneca has a 52-week low of $28.43 and a 52-week high of $36.75.
AstraZeneca (NYSE:AZN) last released its quarterly earnings results on Friday, May 18th. The company reported $0.48 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.28 by $0.20. AstraZeneca had a net margin of 12.61% and a return on equity of 30.12%. The firm had revenue of $5.18 billion during the quarter, compared to analyst estimates of $5.24 billion. During the same quarter in the prior year, the firm earned $0.99 EPS. The business’s revenue for the quarter was down 4.2% compared to the same quarter last year. analysts expect that AstraZeneca will post 1.7 EPS for the current year.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.